Evidence Level Notice
Claudin18.2-directed CAR-T therapy currently has no regulatory approval (FDA, EMA, or NMPA) in any jurisdiction. All patient access is exclusively through clinical trials. Results from early-phase studies may not be reproducible in routine clinical practice. This page describes investigational approaches, not established treatments.
Claudin18.2-Targeted CAR-T Cell Therapy: Investigational Overview
An independent clinical reference for Claudin18.2-directed CAR-T therapy — an investigational approach for gastric, gastroesophageal, and pancreatic adenocarcinomas.
What is Claudin18.2?
Claudin18.2 (CLDN18.2) is a tight junction protein normally expressed in the gastric mucosa, where it is sequestered within tight junctions and largely inaccessible to circulating antibodies or immune cells.
In certain gastrointestinal malignancies — particularly gastric and gastroesophageal junction (GEJ) adenocarcinomas — Claudin18.2 becomes aberrantly exposed on the tumor cell surface, making it a theoretically attractive target for CAR-T therapy.
Critical Distinction from CD19/BCMA: Unlike hematologic targets (CD19 on B-cells, BCMA on plasma cells), Claudin18.2 is expressed in normal gastric tissue. This creates a unique on-target, off-tumor toxicity risk: CAR-T cells may attack healthy gastric mucosa, leading to gastrointestinal toxicity (gastritis, mucosal damage) that is not observed with CD19 or BCMA CAR-T therapies.
For a detailed explanation of how CAR-T cells are engineered to target specific antigens, please refer to our CAR-T Cell Therapy Hub →
Target Malignancies
Claudin18.2-directed CAR-T therapy is under investigation for gastrointestinal adenocarcinomas with high Claudin18.2 expression:
- Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma — primary focus of clinical development
- Pancreatic Ductal Adenocarcinoma (PDAC) — emerging investigational target (early-phase)
Testing Requirement: Claudin18.2 expression must be confirmed by immunohistochemistry (IHC) testing. Patient eligibility for clinical trials is contingent on documented Claudin18.2 positivity (thresholds vary by trial, typically ≥40% of tumor cells).
Investigational Constructs in Active Clinical Trials
Unlike CD19 and BCMA, no Claudin18.2-targeted CAR-T product has received regulatory approval. The table below lists investigational constructs in active clinical development.
| Construct / Code Name | Developer / Sponsor | Phase | Trial Location | Registry |
|---|---|---|---|---|
| CT041 | CARsgen Therapeutics | Phase 1/2 | China | Search → |
| AZD0390 | AstraZeneca | Phase 1 | Multiple (US, EU, Asia) | Search → |
| LM-305 | Legend Biotech | Phase 1 | China, US | Search → |
| Additional academic/industry constructs | Multiple sponsors | Phase 1/2 | Global | Search → |
Note: Clinical trial availability, enrollment status, and eligibility criteria change frequently. The links above direct to live ClinicalTrials.gov search results for "Claudin18.2 CAR-T." Always verify current trial status directly with the sponsor or registry.
Level of Evidence — Explicit Comparison
Claudin18.2 CAR-T is at a materially earlier stage of clinical validation than CD19 or BCMA.
| Target | Evidence Maturity | Regulatory Status | Data Horizon |
|---|---|---|---|
| CD19 | Level 1 Phase III, 8+ years post-marketing |
FDA/EMA/NMPA approved (5+ products) |
2017–present |
| BCMA | Level 1 Phase III, 3+ years post-marketing |
FDA/EMA approved (2 products) |
2021–present |
| Claudin18.2 | Level 2–3 Phase 1/2, single-arm, small cohorts |
No regulatory approval | 2019–present (early-phase only) |
What this means clinically:
- Claudin18.2 CAR-T data come primarily from Phase 1 dose-escalation and Phase 2 single-arm studies with limited patient numbers (typically <50 patients per trial).
- There are no randomized Phase III trials comparing Claudin18.2 CAR-T to standard-of-care.
- Long-term safety and efficacy data beyond 2–3 years are not yet available.
- Results observed in highly selected trial populations may not generalize to broader clinical practice.
International Access Limitations — Honest Assessment
Access to Claudin18.2 CAR-T clinical trials is not guaranteed and is subject to strict eligibility criteria:
- Molecular Eligibility: Patients must have documented Claudin18.2 expression (typically ≥40% of tumor cells by IHC, though thresholds vary by trial).
- Prior Therapy Requirements: Most trials require patients to have progressed on ≥2 lines of standard therapy (chemotherapy, targeted therapy, immunotherapy).
- Performance Status: Patients must meet strict ECOG performance status criteria (typically ECOG 0–1), excluding those with significant comorbidities.
- Organ Function: Adequate cardiac, hepatic, renal, and pulmonary function is required.
- Geographic and Logistical Constraints: Trials are conducted at specific sites. International patients must be able to travel to and remain near the trial site for the duration of treatment and follow-up (often 1–3 months minimum).
- No Guarantee of Enrollment: Meeting eligibility criteria does not guarantee acceptance. Trial sites have limited capacity and may prioritize patients based on specific scientific objectives.
For patients considering international clinical trials: Our platform can facilitate secure transfer of medical records for trial screening, but we cannot pre-approve eligibility or guarantee enrollment. All decisions are made by the trial investigators based on their specific protocol requirements. Request an Information-Based Case Review →